<DOC>
	<DOCNO>NCT01461980</DOCNO>
	<brief_summary>This clinical study ass safety , tolerance immunogenic response MCV4 ( quadrivalent meningococcal polysaccharide conjugate , meningococcal serogroups A , C , Y , W135 ) , Tdap ( diphtheria , tetanus , acellular pertussis ) , bivalent rLP2086 vaccine . Healthy male female subject , age 10 12 year old , randomize 1 3 group . The subject , investigator , site staff sponsor blind injection give throughout study . An unblinded administrator responsible administer vaccination subject unblinded subject randomization order determine subject randomize group 3 may receive catch-up vaccination MCV4 Tdap . A final telephone contact conduct subject 6-months post last vaccination obtain safety information .</brief_summary>
	<brief_title>A Clinical Trial Study Safety , Tolerance Immunogenic Response MCV4 , Tdap Bivalent rLP2086 Vaccine When Given Same Time Children Between Ages 10 Through 12 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Evidence personally sign date informed consent document ( ICD ) indicate subject ( legally authorize representative ) inform pertinent aspect study . Parent /legally authorize representative subject willing able comply schedule visit , laboratory test , study procedure . Male female subject age great equal 10 &lt; 13 year time enrollment . Available entire study period reach telephone . Healthy subject determine medical history , physical examination , judgment investigator . Has receive full series ( 5dose series prefer , 4dose catch series allow ) diphtheria , tetanus pertussis ( whole cell acellular ) vaccine per country specific recommendation applicable time receipt . Male female subject childbearing potential must agree use highly effective method contraception throughout study . Previous vaccination meningococcal serogroup B vaccine . Vaccination diphtheria , tetanus pertussis vaccine within 5 year first study vaccination . Previous vaccination MCV4 vaccine . A previous anaphylactic reaction vaccine vaccinerelated component . Contraindication vaccination MCV4 and/or Tdap vaccine . Subjects receive allergen immunotherapy nonlicensed product receive allergen immunotherapy license product stable maintenance dos . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . A know suspected defect immune system would prevent immune response vaccine , subject congenital acquire defect B cell function , receive chronic systemic ( oral , intravenous intramuscular ) corticosteroid therapy , receive immunosuppressive therapy . Subjects terminal complement deficiency may include . History cultureproven disease cause Neisseria meningitidis Neisseria gonorrhoea . Significant neurological disorder history seizure ( exclude simple febrile seizure ) . Receipt blood product , include immunoglobulin within 6 month first study vaccination . Current chronic use systemic antibiotic . Any neuroinflammatory autoimmune condition , include , limited , transverse myelitis , uveitis , optic neuritis , multiple sclerosis .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>vaccine</keyword>
	<keyword>rLP2086</keyword>
	<keyword>MCV4</keyword>
	<keyword>Tdap</keyword>
	<keyword>meningitis B</keyword>
	<keyword>N. meningitidis serogroup B</keyword>
	<keyword>adolescent</keyword>
	<keyword>observer-blind</keyword>
</DOC>